US Food and Drug Administration (FDA) commissioner Margaret Hamburg has confirmed that the agency is revoking its approval of the breast cancer indication for Roche’s Avastin medication.

The drug will, however, remain on the market as an approved treatment for particular forms of colon, lung, kidney and brain cancer.

Risks associated with Avastin include high blood pressure, bleeding and haemorrhaging as well as heart attack or failure.

The announcement stems from a decision made in July 2010, in which the FDA Oncologic Drugs Advisory Committee voted 12-1 in favour of removing the drug’s approval.